A retrospective analysis of patients with metastatic NSCLC receiving the anti-PD1 checkpoint inhibitor nivolumab showed that presence of BoM decreased response rates and overall survival compared to patients without BoM [80]. This evidence concerns the gene PDCD1 and non-small cell lung carcinoma.